B · Normal
[Chen Jining meets with Swiss Roche Group Chairman of the Board of Directors Schwan] On November 18th, Shanghai Municipal Party Committee Secretary Chen Jining met with Swiss Roche Group Chairman of the Board of Directors Schwan and his delegation this morning. Chen Jining introduced the latest development situation of Shanghai's health undertakings and biomedical industry. He said that we have anchored the goal of building a healthy Shanghai and promoted the protection of people's health as an important livelihood and welfare plan. Biomedicine is one of the three leading industries that Shanghai focuses on developing. We continue to improve policy measures, strengthen basic research, support the conduct of international multi-center clinical trials, establish a service mechanism for the launch of key innovative pharmaceutical devices, accelerate diversified payments, and promote international cooperation. As a member of the Shanghai Mayor's International Entrepreneur Advisory Council, Luo has long-term good cooperation with Shanghai and actively provides suggestions for urban development.
Welcome to seize development opportunities such as the acceleration of scientific and technological innovation and changes in the consumer market, strengthen practical cooperation in all fields of health and health, deepen exchanges and mutual learning around promoting artificial intelligence to empower innovation in the entire biopharmaceutical industry chain, promote health insurance development and product development, launch new projects in Shanghai, and promote the launch of more new drugs. We will continue to create a market-oriented, legal and international first-class business environment, carefully listen to the opinions and suggestions of enterprises, provide efficient and convenient services, and support enterprises to achieve greater development. Schwan said that he came to Shanghai to participate in Roche’s 100th anniversary celebration of serving China and the completion ceremony of its biopharmaceutical production base, witnessing a century of cooperation and opening a new chapter in future cooperation. While investing in the construction of a biopharmaceutical production base in Shanghai and promoting the local production of more innovative drugs, we will also focus on building an early research and development platform to better connect drug discovery and pre-clinical stage to benefit the majority of patients. We will continue to strengthen our business and R&D layout in Shanghai, deepen open cooperation and mutual learning of experience, and make greater contributions to the development of health care in China and Shanghai. (Shangguan News)
Comments